SapiensBio is a data-driven technology-based drug discovery company founded in 2018 with headquarters and wet lab facilities located in Seongnam-si, South Korea.
Scientists at SapiensBio have developed a novel platform, Sapientia, a highly efficient technological platform which governs a novel approach to drug discovery by creating a well-organized workflow that fully integrates Machine Learning technology with wet lab experimentation.
Using Sapientia, SapiensBio aims to drastically accelerate the drug discovery process, from novel target identification and validation to clinical candidate selection. In its first and most advanced program, SapiensBio has been able to identify and validate a novel target for idiopathic pulmonary fibrosis (IPF) and generate several novel and patentable lead series in 18 months. SapiensBio currently has programs in two major therapy areas, fibrosis and neurodegenerative diseases, exploring novel targets. SapiensBio’s pipeline includes two novel targets for the treatment of different fibrotic conditions and two separate novel programs for the treatment of Alzheimer’s disease and other neurodegenerative conditions.
The most advanced program, SBC101, for the treatment of idiopathic pulmonary fibrosis is currently in the latest stage of lead optimization undergoing safety evaluation following chronic treatment, after successfully completed in vitro and in vivo efficacy studies.
SapiensBio, with its Sapientia platform, aims to be a resource for large and medium size drug development companies interested in starting new and novel drug discovery programs by providing the means to identify novel targets and generate new chemical lead that can rapidly yield a clinical candidate.